Rain Therapeutics Closes $18 Million Series A Financing

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
42
Rain Therapeutics Closes $18 Million Series A Financing

FREMONT, Calif., May 21, 2018 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on biomarker-driven, small molecule therapeutics for patients with cancer, today announced the closing of a tranched Series A financing of $18.4 million. The financing was led by San Francisco-based, Biotechnology Value Fund (BVF) and followed by Perceptive Advisors, Auckland UniServices Limited’s Inventors Fund and other private investors. BVF’s Gorjan Hrustanovic, Ph.D., will join the Rain Board of Directors in conjunction with the financing. The Series A round follows a $1 million convertible note financing completed in late-2017.

Rain plans to use the proceeds to advance the clinical development of its lead program, Tarloxotinib (Tarlox), in patients with EGFR and ErbB Exon 20 insertion mutations in non-small cell lung cancer (NSCLC). The company intends to commence a Phase 2 study in patients with EGFR and ErbB Exon 20 insertion mutations in NSCLC in the first half of 2019.

“With the proceeds from recent financings we can complete a Phase 2, proof-of-concept study and continue to advance Tarloxotinib,” said Avanish Vellanki, Rain’s co-founder and chief executive officer. “Our goal is to provide Exon 20 patients with a novel treatment option that results in strong anti-tumor responses while avoiding the debilitating, dose-limiting EGFR toxicities in the gut and skin that are associated with conventional small molecule inhibitors.”

“Targeting wildtype EGFR, or wildtype EGFR- like tumors has always been very challenging with conventional small molecule inhibitors because of the abundance of EGFR in healthy tissues,” said Robert Doebele, M.D., Ph.D., co-founder of Rain Therapeutics, and associate professor of medicine and director of the Thoracic Oncology Research Initiative at the University of Colorado.  “Patients with Exon 20 lung cancer show an addiction to EGFR, however the resemblance of EGFR Exon 20 to EGFR wildtype suggests most conventional strategies will be limited by toxicity. With its novel mechanism of action, Tarlox has the potential to address this inherent, unmet challenge in Exon 20 patients.”

Rain has worldwide development and commercialization rights for Tarlox through an exclusive license to technology developed at the University of Auckland.

About Rain Therapeutics Inc.

Rain Therapeutics Inc. is a privately-held biotechnology company developing biomarker-driven small molecule therapeutics for patients with cancer. Rain’s lead program, Tarloxotinib, is a hypoxia-activated prodrug of a potent pan-ErbB inhibitor in development as a treatment for non-small cell lung cancer patients with EGFR / ErbB Exon 20 insertion mutations. Rain Therapeutics Inc., has worldwide development and commercialization rights for Tarloxotinib through an exclusive license from the University of Auckland. For more information, visit www.rainthera.com

Media Contact Cait Williamson, Ph.D. LifeSci Public Relations +1.949.290.4945 cait@lifescipublicrelations.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Rare Stellar Merger Validates RIT Theory in Nature

Updated Category News Views 62

One star swallowed another’s orbit, and astronomy finally caught the evidence. That is the plain-English punch of the observation called AT 2025abao in the Andromeda Galaxy, and it is a meaningful one for Jason Nordhaus and his colleagues at Rochester Institute of Technology. On Nov. 18, research published in Nature validated a scenario Nordhaus’s team had predicted...

Continue Reading
America's Group Adds Swansea to Its UK Auction Map

Updated Category News Views 128

A Welsh Lane Joins a Larger Road Port Talbot just became a small but telling dot on America's Group's international map. The company has acquired Swansea Motor Vehicle Auction Limited, a long-standing South Wales wholesale and remarketing operation, and plans to run it under the G3 brand. This is not the sort of deal that makes markets levitate. It is the sort that tells...

Continue Reading
Berlin Heals Puts Microcurrent Therapy to a Real Test

Updated Category News Views 56

A silent electrical signal is heading into the sort of trial that separates intriguing ideas from credible medical evidence. Berlin Heals Holding AG has initiated C-MIC IV, an international randomized, double-blind, sham-controlled study of its implanted microcurrent therapy for symptomatic heart failure. The first patient has already been implanted in Kragujevac, Serbia....

Continue Reading
ROHM's GaN PFC Chip Targets the Power-Supply Squeeze

Updated Category News Views 0

Power supplies are where a lot of sleek electronics quietly lose the plot, and ROHM is taking a proper swing at that problem. Its new BM85060FV is a totem-pole power factor correction controller built for gallium nitride, or GaN, high-frequency switching in AC-DC power supplies. The headline is not subtle: ROHM says a 300 to 500 W system using the chip can reach 99%...

Continue Reading
JOYY’s Ad Engine Gives Q3 Growth Some Real Teeth Now

Updated Category News Views 93

Three engines are finally pulling the cart at JOYY, and that is a far more interesting sight than another quarter of livestreaming merely holding together. The company reported third-quarter 2026 revenue of US$624.6 million, up 15.6% from a year earlier and 5.7% sequentially. Those are sturdy numbers, especially for a business that investors have long tended to box in as...

Continue Reading
Replit Bets on Trusted Creators to Sell AI Agents at Work

Updated Category News Views 52

Forty-five creators may sound like a marketing footnote, but Replit is aiming at a real enterprise bottleneck: people do not buy grand AI slogans; they buy proof that a messy internal problem can actually get fixed. Its newly launched Replit & Co. program puts business and technology creators in front of that problem, with product access, demonstrations and direct contact...

Continue Reading
Term or Whole Life: Costs, Coverage, and Trade-Offs

Updated Category News Views 56

A life insurance choice can sit quietly in a drawer for years, then become brutally important at exactly the wrong moment. Laura Wood's November 18, 2026 comparison of term and whole life insurance is useful for that reason: it keeps dragging the conversation back to the unglamorous stuff that actually matters—how long coverage lasts, what it costs, and whether a...

Continue Reading
OCEG Faces China's Demographic Test After 40 Years

Updated Category News Views 83

A school group that once opened 35 kindergartens in a year is admitting the old playbook has run its course. That is the real message behind Oriental Cambridge Education Group's 40th-anniversary talk, not the balloons and ceremonial language. OCEG operates more than 170 institutions across 39 Chinese cities, and its chairman, Yu Yue, says the next chapter will be judged...

Continue Reading
U.S. Patriot's Veteran Hiring Earns a Real National Nod

Updated Category News Views 58

A workforce award can be cheap wallpaper, but this one has some heft. U.S. Patriot, the veteran-founded and veteran-led military goods retailer owned by GALLS, landed on Military Times’ 2026 Best for Vets: Employers list, placing third in retail and first in Kentucky. The recognition covers 250 organizations, and this is U.S. Patriot’s fourth consecutive appearance....

Continue Reading
Italian Wine Faces U.S. Slump and New Market Openings

Updated Category News Views 133

American demand has put a cork in the easy story, and Italian wine producers cannot pretend otherwise. In the first nine months of 2026, U.S. imports of Italian wine dropped 18.4% by value. That is painful because the United States remains Italy's largest destination market by value, not some side shelf that can be ignored until conditions improve. Still, the broader U.S....

Continue Reading

Top 5 Most Recently Viewed Articles

Proaction Secures $4.2M to Challenge Legacy Fleet Firms

Updated Category News Views 129

Fleet Management: A Market Ripe for Disruption You ever cruised past an old clunker of a business model and thought, "Now there's a setup ripe for a rethink"? That's exactly what Proaction's up to with their recent $4.2 million cash injection. For anyone keeping tabs on the legacy fleet management scene, it’s like watching someone take a claw hammer to a creaky old...

Continue Reading
Mission Bio Unveils Groundbreaking Solution for Genome Analysis

Updated Category News Views 161

Mission Bio dropped the bomb back in 2024 with its Tapestri Genome Integrity CNV Solution, a serious piece of kit aimed at transforming how researchers tackle genomic integrity. This ain't just another offering; it’s the first single-cell high-throughput solution that measures genome-wide copy number variations (CNVs). Think of it as a lifeline for those deep in...

Continue Reading
Varonis Shines as a Leader in Data Security Platforms

Updated Category News Views 286

Varonis Receives Prestigious Recognition in Data Security Varonis Systems, Inc. (Nasdaq: VRNS) is excited to receive acknowledgment as a Leader within the data security landscape, as highlighted by a prominent research firm in their latest report. This recognition emphasizes Varonis’ commitment to securing data effectively while continuously evolving their platform to...

Continue Reading
CocoFest 2025: Embracing Community and Wellness Together

Updated Category News Views 497

CocoFest 2025: A Celebration of Community and Wellness CocoFest is returning for its third rendition, bringing together people for a day dedicated to celebrating love and wellness. This exciting event will take place on a Saturday at the Boca Raton Innovation Campus, showcasing how love can enhance our lives in various ways. What to Expect at CocoFest 2025 The festival...

Continue Reading
Innovative Speech Therapy Game Enhances Learning for Kids

Updated Category News Views 169

Innovative Speech Therapy Game Revolutionizes Learning In a vibrant city, an inventive mind has crafted a special game designed to make speech therapy more engaging for children. This game, known as LINGUA TOKENS, aims to bring excitement into learning fundamental speech skills. With a focus on fun, children aged 4 to 9 can enhance their articulation through play-based...

Continue Reading